This provider's $5.8M in total Medicare payments ranks in the 94th percentile of Ambulatory Surgical Center providers nationally.
Medicare payments to this provider grew 193% from 2021 to 2023.
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 112% in 2022
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2021 | $7.0K | $2.3K | 3.07x | $4.7K | $965.9K | 534 | 497 |
| 2022 | $6.3K | $1.9K | 3.22x | $4.3K | $2.1M | 1.3K | 1.2K |
| 2023 | $6.0K | $1.8K | 3.24x | $4.1K | $2.8M | 2.2K | 2.1K |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| 64590 | Insertion or replacement of peripheral or gastric neurostimulator generator | 111 | $1.6M | $14.8K | 1.95x |
| C9740 | Cystourethroscopy, with insertion of transprostatic implant; 4 or more implants | 162 | $915.6K | $5.7K | 2.04x |
| 52356 | Crushing of stone in urinary duct (ureter) with stent using an endoscope | 344 | $572.8K | $1.7K | 3.96x |
| 55700 | Biopsy of prostate gland | 862 | $560.8K | $650.54 | 6.76x |
| 50590 | Shock wave crushing of kidney stones | 495 | $504.8K | $1.0K | 7.35x |
| 64561 | Insertion of sacral nerve neurostimulator electrode array | 78 | $300.1K | $3.8K | 2.03x |
| 52332 | Insertion of stent in urinary duct (ureter) using an endoscope | 258 | $247.0K | $957.30 | 4.80x |
| 51715 | Injection of implant material beneath lining of bladder and/or urethra using an endoscope | 110 | $170.3K | $1.5K | 1.98x |
| 64581 | Incision to insert sacral nerve neurostimulator electrodes | 38 | $147.5K | $3.9K | 2.08x |
| 52204 | Biopsy of the bladder using an endoscope | 137 | $86.8K | $633.82 | 6.94x |
| 52235 | Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 70 | $79.5K | $1.1K | 4.05x |
| 52234 | Destruction and/or removal of (0.5 to 2.0 centimeters) small growths of the bladder using an endoscope | 52 | $59.0K | $1.1K | 4.05x |
| 52351 | Diagnostic exam of bladder, urethra, and ureter or kidney using an endoscope | 54 | $58.9K | $1.1K | 4.22x |
| 52240 | Destruction and/or removal of large growth of bladder using an endoscope | 34 | $58.8K | $1.7K | 3.81x |
| 52648 | Complete laser vaporization of prostate including control of bleeding using an endoscope | 33 | $57.0K | $1.7K | 5.21x |
| 52317 | Crushing, fragmenting, and removal of (less than 2.5 centimeters) bladder stone | 55 | $56.2K | $1.0K | 4.50x |
| 55874 | Injection of biodegradable material next to prostate | 18 | $50.3K | $2.8K | 2.36x |
| 55040 | Removal of fluid accumulation in one testicle and sperm reservoir | 43 | $50.3K | $1.2K | 3.93x |
| 52318 | Crushing, fragmenting, and removal of bladder stones, more than 2.5 cm | 37 | $38.8K | $1.0K | 4.38x |
| 52287 | Examination with injections of chemical for destruction of bladder using an endoscope | 59 | $36.7K | $622.28 | 7.07x |
This provider submits charges 4.15 times higher than what Medicare actually pays.
A markup ratio of 4.15x means for every $100 Medicare pays, this provider initially charges $415. This is higher than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Ambulatory Surgical Center providers in PA for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Main Line Surgery Center, Llc | Bala Cynwyd, PA | $38.7M | ✓ Clear |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data